Loading organizations...
§ Private Profile · Eindhoven, Netherlands
Precision oncology company commercializing mRNA-based diagnostic tests and software for targeted cancer therapies, predicting patient responses.
InnoSIGN, based in Eindhoven, Netherlands, develops and commercializes OncoSIGNal, an mRNA-based technology that profiles pathway activity in cancer and immune cells to predict patient responses to targeted therapies. Its proprietary diagnostic technology leverages cloud-based data analysis software with a database of over 100,000 profiles for research-use-only tests on conventional PCR machines, also offering the InnoSIGN Portal for disease driver identification. The company has raised $9.2 million in venture funding, including $7.33 million in early 2022 and $1.2 million in June 2022. Lead investors include Casdin Capital, Thuja Capital, BOM, and Rivermount. InnoSIGN spun out from Philips in 2022, with Philips retaining a minority stake. The company was founded in 2022 by Sigi Neerken and Paul van de Wiel.
InnoSIGN has raised $8.0M across 1 funding round.
InnoSIGN has raised $8.0M in total across 1 funding round.
InnoSIGN has raised $8.0M in total across 1 funding round.
InnoSIGN's investors include Life Science Angels, BOM, Casdin Capital, Thuja Capital.
InnoSIGN has raised $8.0M across 1 funding round. Most recently, it raised $8.0M Series A in March 2022.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Mar 1, 2022 | $8M Series A | — | Life Science Angels, BOM, Casdin Capital, Thuja Capital | Announced |
InnoSIGN is a clinical-stage biotechnology company specializing in precision medicine, particularly within oncology. It develops the OncoSIGNal technology, an mRNA-based pathway activity profiling platform that translates complex molecular data into functional insights about cell signaling pathways driving disease. This technology serves healthcare providers, researchers, and pharmaceutical developers by improving understanding of cancer mechanisms and guiding personalized therapeutic decisions. InnoSIGN has demonstrated growth momentum through its clinical adoption in breast cancer diagnostics and its expanding database of over 100,000 pathway activity profiles supporting drug and diagnostic development[1][2][5].
Founded in 2022 and headquartered in Eindhoven, Netherlands, InnoSIGN emerged from expertise in drug discovery, companion diagnostics (CDx) development, and market access. The company was created to address the need for more precise and actionable insights into disease biology, especially cancer, by leveraging mRNA-based technologies. A pivotal moment was the development and commercialization of the OncoSIGNal platform, which has since been made available for clinical use in the US and Europe. In March 2024, Eric Lindquist, with a background in genetics, cell biology, and business, was appointed CEO, marking a new phase in leadership and growth[1][3][4].
InnoSIGN operates at the intersection of biotechnology, precision medicine, and digital health, riding the trend toward personalized oncology treatments driven by molecular diagnostics. The timing is critical as oncology increasingly shifts from one-size-fits-all therapies to targeted, pathway-driven interventions. Market forces such as growing demand for precision diagnostics, advances in mRNA technology, and the need for better predictive biomarkers favor InnoSIGN’s approach. By enabling deeper understanding of disease mechanisms, InnoSIGN influences drug development pipelines and clinical decision-making, contributing to a more data-driven, patient-centric healthcare ecosystem[1][2][5].
Looking ahead, InnoSIGN is poised to expand its clinical applications beyond breast cancer and deepen collaborations with pharmaceutical companies for drug development. Trends such as integration of multi-omics data, AI-driven analytics, and broader adoption of precision oncology will shape its trajectory. The company’s influence is likely to grow as it democratizes access to pathway activity profiling, potentially becoming a standard tool in oncology diagnostics and personalized treatment planning. Continued innovation, patent protection, and strategic leadership under CEO Eric Lindquist will be key to sustaining momentum and impact in the evolving biotech landscape[1][3][5].